Over a decade ago, when SARS (Severe Acute Respiratory Syndrome) was first detected in China, it took significant time to identify the virus and to understand how the disease spread among affected populations.
Most Recent Posts
PhRMA president & CEO John Castellani and Jim Greenwood, president and CEO of the Biotechnology Industry Association (BIO) team-up at Patent Docs to c
Drugfree.org kicked off an amazing campaign to promote consumer awareness of safe medicine use and disposal - if you haven't seen their parent and teacher toolkits, you're missing out. And while their Project's kickoff may be over, our work to reduce prescription drug abuse continues on. In keeping that fire burning, I've asked PDMP Center of Excellence at Brandeis University Director John Eadie to guest blog post about what's going on in their neck of the woods.
In the parlance of corporate mergers, "Day 1" is a critical moment of transition. While not without challenges, Day 1 often brings a sense of excitement, promising growth platforms and long-term opportunities. When it comes to regulatory policy, this marks the biopharmaceutical research sector's Day 1.
Scientific American has several good blogs, and one of my favorites is Gary Stix's Talking Back (@gstix1) which covers neuroscience.
PhRMA issued the following statement on an article published today by Bloomberg.
"An article published today by Bloomberg does not accurately reflect PhRMA's position on Medicare Part D or other health care policy issues. The article is based on improperly obtained internal documents that were in draft form. The documents do not contain official PhRMA policy positions, which are set by the organization's Board of Directors.
While we've long been active on the issue of prescription drug abuse, the next few weeks will be a particularly important time to take action with The Medicine Abuse Project.